Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains

• Published in: bioRxiv
• Main Authors: Case, James Brett, Mackin, Samantha, Errico, John, Chong, Zhenlu, Madden, Emily A, Guarino, Barbara, Schmid, Michael A, Rosenthal, Kim, Ren, Kuishu, Jung, Ana, Droit, Lindsay, Handley, Scott A, Halfmann, Peter J, Kawaoka, Yoshihiro, Crowe, James E, Fremont, Daved H, Virgin, Herbert W, Yueh-Ming Loo, Esser, Mark T, Purcell, Lisa A, Corti, Davide, Diamond, Michael S
• Format: Paper
• Language: English
• Published: Cold Spring Harbor Cold Spring Harbor Laboratory Press 18.03.2022; Cold Spring Harbor Laboratory
• Edition: 1.1
• Subjects: ACE2; Angiotensin-converting enzyme 2; Biotechnology; Bronchopulmonary infection; Cell culture; Employees; Fc receptors; Immunotherapy; Laboratories; Microbiology; Monoclonal antibodies; Severe acute respiratory syndrome coronavirus 2; Spike protein; Transgenic mice

Omicron variant strains encode large numbers of changes in the spike protein compared to historical SARS-CoV-2 isolates. Although in vitro studies have suggested that several monoclonal antibody therapies lose neutralizing activity against Omicron variants1-4, the effects in vivo remain largely unkn...